Equities Analysts Set Expectations for CRBP Q2 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Investment analysts at B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. B. Riley analyst K. Patel now anticipates that the biopharmaceutical company will post earnings per share of ($1.63) for the quarter, down from their prior estimate of ($0.92). B. Riley has a "Buy" rating on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals' Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.63) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($5.49) EPS and FY2027 earnings at ($5.50) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.13).

Several other research firms have also commented on CRBP. William Blair initiated coverage on Corbus Pharmaceuticals in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. Jefferies Financial Group cut their price objective on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Royal Bank of Canada dropped their target price on Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Oppenheimer dropped their target price on Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Corbus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $50.88.

Corbus Pharmaceuticals Trading Up 11.0%

NASDAQ:CRBP traded up $0.71 during mid-day trading on Friday, hitting $7.16. The company had a trading volume of 137,405 shares, compared to its average volume of 359,495. The business has a fifty day simple moving average of $6.33 and a 200-day simple moving average of $10.77. Corbus Pharmaceuticals has a 1 year low of $4.64 and a 1 year high of $61.90. The firm has a market capitalization of $87.58 million, a price-to-earnings ratio of -1.53 and a beta of 3.19.

Institutional Trading of Corbus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Orbimed Advisors LLC increased its holdings in Corbus Pharmaceuticals by 28.5% in the fourth quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company's stock valued at $13,833,000 after buying an additional 259,735 shares during the last quarter. Millennium Management LLC increased its holdings in Corbus Pharmaceuticals by 215.0% in the fourth quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company's stock valued at $4,563,000 after buying an additional 263,902 shares during the last quarter. Altium Capital Management LLC increased its holdings in Corbus Pharmaceuticals by 97.4% in the fourth quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company's stock valued at $4,543,000 after buying an additional 190,000 shares during the last quarter. Prosight Management LP increased its holdings in Corbus Pharmaceuticals by 107.7% in the fourth quarter. Prosight Management LP now owns 270,000 shares of the biopharmaceutical company's stock valued at $3,186,000 after buying an additional 140,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Corbus Pharmaceuticals by 5.5% in the fourth quarter. Geode Capital Management LLC now owns 263,532 shares of the biopharmaceutical company's stock valued at $3,110,000 after buying an additional 13,773 shares during the last quarter. 64.64% of the stock is owned by institutional investors.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.